Synlogic Inc (NASDAQ:SYBX) – Equities research analysts at Wedbush raised their Q1 2018 earnings estimates for shares of Synlogic in a report released on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings of ($0.62) per share for the quarter, up from their previous forecast of ($0.84). Wedbush has a “Outperform” rating and a $20.00 price objective on the stock. Wedbush also issued estimates for Synlogic’s Q2 2018 earnings at ($0.65) EPS, Q3 2018 earnings at ($0.69) EPS, Q4 2018 earnings at ($0.73) EPS, FY2018 earnings at ($2.68) EPS, FY2019 earnings at ($2.54) EPS, FY2020 earnings at ($2.37) EPS and FY2021 earnings at ($2.25) EPS.
Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Synlogic from a “hold” rating to a “sell” rating in a research note on Wednesday, November 22nd. ValuEngine lowered Synlogic from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Piper Jaffray Companies assumed coverage on Synlogic in a research note on Monday, January 29th. They issued an “overweight” rating and a $16.00 target price for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $18.75.
Synlogic (SYBX) opened at $9.81 on Friday. The company has a market capitalization of $213.07, a price-to-earnings ratio of -1.04 and a beta of 2.18. Synlogic has a 12 month low of $8.76 and a 12 month high of $23.00.
A number of institutional investors have recently added to or reduced their stakes in SYBX. Artal Group S.A. purchased a new stake in Synlogic during the fourth quarter valued at about $5,335,000. Spark Investment Management LLC purchased a new stake in Synlogic during the fourth quarter valued at about $105,000. Deutsche Bank AG grew its position in Synlogic by 204.0% during the fourth quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 13,200 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Synlogic during the fourth quarter valued at about $191,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.